Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1583-1594

  Zhang, Shenghong ^a,b   Zhong, Bihui ^a   Chen, Minhu ^a   Yang, Li ^a   Yang, Guang ^a   Li, Yuan ^b   Wang, Hong ^c   Wang, Guanjun ^c   Li, Wei ^c   Cui, Jiuwei ^c   Hoffman, Andrew R ^b   Hu, Jifan ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

cancer; cell reprogramming; DNA methylation; epigenetics; epigenotype; histone modification; MAPK signal pathway; matrix; metalloproteinases; TIMPs

Indexed keywords

MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MORPHOLOGY; CARCINOGENICITY; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; MMP GENE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; STOMACH CANCER; TIMP GENE; TUMOR CELL CULTURE; TUMOR GENE; TUMOR INVASION;

CANCER; CELL REPROGRAMMING; DNA METHYLATION; EPIGENETICS; EPIGENOTYPE; HISTONE MODIFICATION; MAPK SIGNAL PATHWAY; MATRIX; METALLOPROTEINASES; TIMPS;

CARCINOGENESIS; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSCRIPTOME;

EID: 84892594857     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28487     Document Type: Article

References (49)

1. Allen M, Louise Jones J,. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011; 223: 162-76.
2. Hojilla CV, Mohammed FF, Khokha R,. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-21.
3. Stamenkovic I,. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-33.
4. Gialeli C, Theocharis AD, Karamanos NK,. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. Febs J 2011; 278: 16-27.
5. Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M,. Gastric cancer-The role of matrix metalloproteinases in tumor progression. Clin Chim Acta 2011; 412: 1725-30.
6. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-85.
7. Kook SH, Jang YS, Lee JC,. Involvement of JNK-AP-1 and ERK-NF-kappaB signaling in tension-stimulated expression of type I collagen and MMP-1 in human periodontal ligament fibroblasts. J Appl Physiol 2011; 111: 1575-83.
8. Lim M, Chuong CM, Roy-Burman P,. PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm Cancer 2011; 2: 298-309.
9. Zucker S, Cao J, Chen WT,. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-50.
10. Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18: 1875-85.
11. Li L, Connelly MC, Wetmore C, et al. Mouse embryos cloned from brain tumors. Cancer Res 2003; 63: 2733-6.
12. Chen HL, Li T, Qiu XW, et al. Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 2006; 25: 5329-38.
13. Kenny PA, Bissell MJ,. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003; 107: 688-95.
14. Maffini MV, Calabro JM, Soto AM, et al. Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol 2005; 167: 1405-10.
15. Watanabe TK, Hansen LJ, Reddy NK, et al. Differentiation of pancreatic acinar carcinoma cells cultured on rat testicular seminiferous tubular basement membranes. Cancer Res 1984; 44: 5361-8.
16. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2009; 107: 40-5.
17. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-20.
18. Hu JF, Vu TH, Hoffman AR,. Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 1996; 271: 18253-62.
19. Hu JF, Nguyen PH, Pham NV, et al. Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol 1997; 11: 1891-8.
20. Li T, Hu JF, Qiu X, et al. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol 2008; 28: 6473-82.
21. Zhang H, Jiao W, Sun L, et al. Intrachromosomal Looping Is Required for Activation of Endogenous Pluripotency Genes during Reprogramming. Cell Stem Cell 2013; 12: 1-6.
22. Zhu XQ, Pan XH, Wang W, et al. Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. Biomaterials 2009; 31: 2779-87.
23. Chen M, Zhang H, Wu J, et al. Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway. Biomaterials 2012; 33: 5514-23.
24. Zhang H, Niu B, Hu JF, et al. Interruption of intrachromosomal looping by CTCF decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 2011; 193: 475-87.
25. Vizioli MG, Sensi M, Miranda C, et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 2010; 29: 3835-44.
26. Zhang H, Wang H, Zhang J, et al. Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors. Mol Ther 2009; 17: 57-64.
27. Wang H, Song X, Zhang H, et al. Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int J Cancer 2012; 130: 443-53.
28. Yao XM, Hu JF, Daniels M, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-73.
29. Jin H, Pan Y, He L, et al. p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer. Mol Cancer Res 2007; 5: 423-33.
30. Park IK, Kim BJ, Goh YJ, et al. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int J Cancer 1997; 71: 867-73.
31. Park HS, Kim GY, Nam TJ, et al. Antiproliferative activity of fucoidan was associated with the induction of apoptosis and autophagy in AGS human gastric cancer cells. J Food Sci 2011; 76: T77-83.
32. Takahashi K, Okita K, Nakagawa M, et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2: 3081-9.
33. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
34. Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-42.
35. Westermarck J, Holmstrom T, Ahonen M, et al. Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38. Matrix Biol 1998; 17: 547-57.
36. Laird PW,. Cancer epigenetics. Hum Mol Genet 2005; 14: R65-76.
37. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
38. Felsher DW,. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003; 3: 375-80.
39. Kapila S, Xie Y, Wang W,. Induction of MMP-1 (collagenase-1) by relaxin in fibrocartilaginous cells requires both the AP-1 and PEA-3 promoter sites. Orthod Craniofac Res 2009; 12: 178-86.
40. Aho S, Rouda S, Kennedy SH, et al. Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor. Eur J Biochem 1997; 247: 503-10.
41. Westermarck J, Seth A, Kahari VM,. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997; 14: 2651-60.
42. Treisman R,. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996; 8: 205-15.
43. Robinson MJ, Cobb MH,. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6.
44. Pei Y, Harvey A, Yu XP, et al. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 2006; 14: 749-58.
45. Lin ML, Lu YC, Chung JG, et al. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 2010; 49: 783-97.
46. Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17: 1969-78.
47. Stetler-Stevenson WG,. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008; 1: re6.
48. Duffy MJ, McGowan PM, Gallagher WM,. Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-93.
49. Jiang Y, Goldberg ID, Shi YE,. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.